School of Public Health, Xinjiang Medical University, Urumqi, China.
Ili Kazakh Autonomous Prefecture Center for Disease Control and Prevention, Ili Kazakh Autonomous Prefecture, China.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2394255. doi: 10.1080/21645515.2024.2394255. Epub 2024 Aug 29.
In the post-COVID-19 pandemic era, influenza virus infections continuously lead to a global disease burden. Evaluating vaccine effectiveness against influenza infection is crucial to inform vaccine design and vaccination strategy. In this study, we recruited 1120 patients with influenza-like illness (ILI) who attended fever clinics of 4 sentinel hospitals in the Ili Kazakh Autonomous Prefecture, Xinjiang Uygur Autonomous Region, China, from January 1 to April 7, 2024. Using a test-negative design, we estimated influenza vaccine effectiveness (VE) of 54.7% (95% CrI: 23.7, 73.1) against medical-attended influenza infection, with 62.3% (95% CrI: 29.3, 79.8) against influenza A, and 51.2% (95% CrI: 28.7, 83.0) against influenza B. Despite the moderate VE estimated in this study, influenza vaccination remains the most important approach to prevent influenza at the community level.
在后 COVID-19 大流行时代，流感病毒感染持续导致全球疾病负担。评估流感感染疫苗的有效性对于指导疫苗设计和接种策略至关重要。在这项研究中，我们招募了 1120 名患有流感样疾病 (ILI) 的患者，他们于 2024 年 1 月 1 日至 4 月 7 日期间前往中国新疆维吾尔自治区伊犁哈萨克自治州的 4 家哨点医院的发热诊所就诊。使用病例对照设计，我们估计了针对医疗就诊的流感感染的流感疫苗有效性 (VE) 为 54.7%（95%CrI：23.7，73.1），对甲型流感的有效性为 62.3%（95%CrI：29.3，79.8），对乙型流感的有效性为 51.2%（95%CrI：28.7，83.0）。尽管本研究估计的 VE 为中等水平，但流感疫苗接种仍然是预防社区层面流感的最重要方法。
